• Xiao-Wei Wang, Qi Sun, Shi-Bin Xu, Chao Xu, Chen-Jie Xia, Qi-Ming Zhao, Hua-Hui Zhang, Wei-Qiang Tan, Lei Zhang, and Shu-Dong Yao.
• Department of Plastic Surgery, Zhejiang Hospital.
• Medicine (Baltimore). 2021 May 21; 100 (20): e26040e26040.

BackgroundTumor-specific DNA methylation can potentially be a useful indicator in cancer diagnostics and monitoring. Sarcomas comprise a heterogeneous group of mesenchymal neoplasms which cause life-threatening tumors occurring throughout the body. Therefore, potential molecular detection and prognostic evaluation is very important for early diagnosis and treatment.MethodsWe performed a retrospective study analyzing DNA methylation of 261 patients with sarcoma from The Cancer Genome Atlas (TCGA) database. Cox regression analyses were conducted to identify a signature associated with the overall survival (OS) of patients with sarcoma, which was validated in a validation dataset.ResultsThree DNA methylation signatures were identified to be significantly associated with OS. Kaplan-Meier analysis showed that the 3-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training (first two-thirds) and validation datasets (remaining one-third). Receiver operating characteristic (ROC) analysis confirmed that the 3-DNA methylation signature exhibited high sensitivity and specificity in predicting OS of patients. Also, the Kaplan-Meier analysis and the area under curve (AUC) values indicated that the 3-DNA methylation signature was independent of clinical characteristics, including age at diagnosis, sex, anatomic location, tumor residual classification, and histological subtypes.ConclusionsThe current study showed that the 3-DNA methylation model could efficiently function as a novel and independent prognostic biomarker and therapeutic target for patients with sarcoma.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

37 keywords...

hide…